TY - JOUR
T1 - Incidence of Uveitis in Patients With Axial Spondylarthritis Treated With Biologics or Targeted Synthetics
T2 - A Systematic Review and Network Meta-Analysis
AU - Bechman, Katie
AU - Yang, Zijing
AU - Adas, Maryam
AU - Nagra, Deepak
AU - S. Uğuzlar, Ali
AU - Russell, Mark D.
AU - Wilson, Nicky
AU - Steer, Sophia
AU - Norton, Sam
AU - Galloway, James
N1 - Publisher Copyright:
© 2023 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
PY - 2024/5
Y1 - 2024/5
N2 - ObjectiveAnterior uveitis is a common extra-articular manifestation of axial spondyloarthritis (AxSpA). We set to evaluate the risk of anterior uveitis (AU) with biologics and synthetic disease-modifying drugs in AxSpA.MethodsWe conducted a systematic review and meta-analysis to identify phase II/III double-blinded randomized controlled trials of anti–tumor necrosis factor (TNF) monoclonal antibodies (mAb), anti–interleukin-17 (anti–IL-17), and Janus kinase inhibitors (JAKi) in AxSpA. Patient-exposure years (PEY) were calculated using the per-protocol approach. Incidence rate (IR) of AU/100 person-years were calculated by treatment group using the random effects approach. Network meta-analysis (NMA) was used to estimate risk of AU in treatment groups, expressed as IR ratios (IRRs). Bias was assessed using the Cochrane Risk of Bias-2 tool.ResultsForty-four trials were included: 17 anti-TNF mAb (1,004 PEY), 9 etanercept (180 PEY), 13 anti–IL-17 (1,834 PEY), and 6 JAKi (331 PEY). The IR of AU were as follows for anti-TNF mAb: 4.1, 95% confidence interval (CI) 0–8.5; etanercept: 5.4, 95% CI 0–16.0; anti–IL-17: 2.8, 95% CI 1.6–4.1; JAKi: 1.5, 95% CI 0.0–3.0; and placebo: 10.8, 95% CI 7.4–14.1. In NMA, IRRs of treatments compared with placebo were as follows for anti-TNF mAb: 0.32, 95% CI 0.10–1.04; etanercept 0.42, 95% CI 0.08–2.38; anti–IL-17: 0.43, 95% CI 0.19–0.98; and JAKi: 0.32, 95% CI 0.06–1.67. Comparisons between anti-TNF mAb, anti–IL-17, and JAKi did not demonstrate any significant difference in AU risk. Using the surface under the cumulative ranking curve approach to rank AU risk, anti-TNF mAbs were associated with the lowest risk followed by JAKi, anti–IL-17, and etanercept. All treatments were ranked superior to placebo.ConclusionAnti-TNF mAbs, JAKi, and anti–IL-17 appear protective against AU events in individuals with AxSpA, with no significant differences in risk of AU between treatments.
AB - ObjectiveAnterior uveitis is a common extra-articular manifestation of axial spondyloarthritis (AxSpA). We set to evaluate the risk of anterior uveitis (AU) with biologics and synthetic disease-modifying drugs in AxSpA.MethodsWe conducted a systematic review and meta-analysis to identify phase II/III double-blinded randomized controlled trials of anti–tumor necrosis factor (TNF) monoclonal antibodies (mAb), anti–interleukin-17 (anti–IL-17), and Janus kinase inhibitors (JAKi) in AxSpA. Patient-exposure years (PEY) were calculated using the per-protocol approach. Incidence rate (IR) of AU/100 person-years were calculated by treatment group using the random effects approach. Network meta-analysis (NMA) was used to estimate risk of AU in treatment groups, expressed as IR ratios (IRRs). Bias was assessed using the Cochrane Risk of Bias-2 tool.ResultsForty-four trials were included: 17 anti-TNF mAb (1,004 PEY), 9 etanercept (180 PEY), 13 anti–IL-17 (1,834 PEY), and 6 JAKi (331 PEY). The IR of AU were as follows for anti-TNF mAb: 4.1, 95% confidence interval (CI) 0–8.5; etanercept: 5.4, 95% CI 0–16.0; anti–IL-17: 2.8, 95% CI 1.6–4.1; JAKi: 1.5, 95% CI 0.0–3.0; and placebo: 10.8, 95% CI 7.4–14.1. In NMA, IRRs of treatments compared with placebo were as follows for anti-TNF mAb: 0.32, 95% CI 0.10–1.04; etanercept 0.42, 95% CI 0.08–2.38; anti–IL-17: 0.43, 95% CI 0.19–0.98; and JAKi: 0.32, 95% CI 0.06–1.67. Comparisons between anti-TNF mAb, anti–IL-17, and JAKi did not demonstrate any significant difference in AU risk. Using the surface under the cumulative ranking curve approach to rank AU risk, anti-TNF mAbs were associated with the lowest risk followed by JAKi, anti–IL-17, and etanercept. All treatments were ranked superior to placebo.ConclusionAnti-TNF mAbs, JAKi, and anti–IL-17 appear protective against AU events in individuals with AxSpA, with no significant differences in risk of AU between treatments.
UR - http://www.scopus.com/inward/record.url?scp=85190771723&partnerID=8YFLogxK
U2 - 10.1002/art.42788
DO - 10.1002/art.42788
M3 - Article
C2 - 38116697
AN - SCOPUS:85190771723
SN - 2326-5191
VL - 76
SP - 704
EP - 714
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
IS - 5
ER -